Kaken Pharmaceutical Co., Ltd.
Earnings Report Supplemental Materials: FY2027 Q2 (Interim) Results
FY2027 Q2 (interim) results. Revenue was 76,871 million yen, cost of sales was 36,879 million yen, and gross profit was 39,991 million yen. Selling, general and administrative expenses were 40,891 million yen, and research and development expenses were 20,585 million yen. Operating income was -899 million yen (worsened YoY), ordinary income was -206 million yen, and net income attributable to owners of parent was 2,144 million yen. Overseas sales were 13,102 million yen, with nine months of contribution from the Aadi acquisition. Comparisons with planned figures are also provided.
Key Figures
- Revenue: 76,871 million yen
- Overseas Sales: 13,102 million yen
- Net Income Attributable to Owners of Parent: 2,144 million yen
AI要約
Key Points of Performance
On a consolidated basis for FY2027 Q2, revenue was 76,871 million yen and overseas sales were 13,102 million yen, exceeding the prior-year period; however, operating income widened to a loss of -899 million yen. Ordinary income was -206 million yen, and net income attributable to owners of parent was 2,144 million yen, indicating a significant improvement in net profit. Profit and loss recognition from the acquisition of Aadi was recorded for nine months. The planned revenue for the fiscal year is 89,900 million yen.
Segments, Pipeline and Overseas Expansion
The Pharmaceuticals segment drives domestic and international sales. For exported products, progress has been made on domestic application of efinaconazole, and parts of the pipeline such as KP-001 are in Phase III and PK stages. The increase in overseas sales also affects the sales composition of major domestic pharmaceuticals. Profit and loss recognition related to the Aadi acquisition has an impact, so attention is required regarding transitions in financial indicators.
Revenue Trend
Operating Income Trend
Kaken Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
